IRLAB Therapeutics
1.25 SEK
-2.95 %
Less than 1K followers
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.95 %
-19.15 %
-30.56 %
-36.55 %
-39.32 %
-81.64 %
-86.41 %
-96.39 %
-88.58 %
IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.
Read moreMarket cap
106.17M SEK
Turnover
93.21K SEK
Revenue
57.46M
EBIT %
-162.55 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.6
2026
Extraordinary general meeting '26
17.6
2026
General meeting '26
26.8
2026
Interim report Q2'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB
IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools